ATE228566T1 - Verfahren zur herstellung von fusionsproteinen - Google Patents

Verfahren zur herstellung von fusionsproteinen

Info

Publication number
ATE228566T1
ATE228566T1 AT96113414T AT96113414T ATE228566T1 AT E228566 T1 ATE228566 T1 AT E228566T1 AT 96113414 T AT96113414 T AT 96113414T AT 96113414 T AT96113414 T AT 96113414T AT E228566 T1 ATE228566 T1 AT E228566T1
Authority
AT
Austria
Prior art keywords
dna sequence
transfected
fusion proteins
restriction site
splice site
Prior art date
Application number
AT96113414T
Other languages
English (en)
Inventor
Stephen D Gillies
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Application granted granted Critical
Publication of ATE228566T1 publication Critical patent/ATE228566T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT96113414T 1989-09-20 1990-08-01 Verfahren zur herstellung von fusionsproteinen ATE228566T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40988989A 1989-09-20 1989-09-20
EP90913419A EP0493418B1 (de) 1989-09-20 1990-08-01 Verfahren zur herstellung von fusionsproteinen

Publications (1)

Publication Number Publication Date
ATE228566T1 true ATE228566T1 (de) 2002-12-15

Family

ID=23622388

Family Applications (2)

Application Number Title Priority Date Filing Date
AT90913419T ATE152174T1 (de) 1989-09-20 1990-08-01 Verfahren zur herstellung von fusionsproteinen
AT96113414T ATE228566T1 (de) 1989-09-20 1990-08-01 Verfahren zur herstellung von fusionsproteinen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT90913419T ATE152174T1 (de) 1989-09-20 1990-08-01 Verfahren zur herstellung von fusionsproteinen

Country Status (9)

Country Link
EP (2) EP0493418B1 (de)
JP (1) JP3051162B2 (de)
AT (2) ATE152174T1 (de)
AU (1) AU633357B2 (de)
CA (1) CA2066612C (de)
DE (2) DE69030579T2 (de)
DK (2) DK0765937T3 (de)
ES (2) ES2187598T3 (de)
WO (1) WO1991004329A1 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US6406697B1 (en) 1989-02-23 2002-06-18 Genentech, Inc. Hybrid immunoglobulins
US5498538A (en) * 1990-02-15 1996-03-12 The University Of North Carolina At Chapel Hill Totally synthetic affinity reagents
US5747334A (en) * 1990-02-15 1998-05-05 The University Of North Carolina At Chapel Hill Random peptide library
WO1992007090A1 (en) * 1990-10-22 1992-04-30 Genentech, Inc. Methods for modifying and detecting the effects on the interaction of modified polypeptides and target substrates
US5525491A (en) * 1991-02-27 1996-06-11 Creative Biomolecules, Inc. Serine-rich peptide linkers
DE69309472T2 (de) * 1992-01-23 1997-10-23 Merck Patent Gmbh, 64293 Darmstadt Fusionsproteine von monomeren und dimeren von antikörperfragmenten
US6103521A (en) * 1995-02-06 2000-08-15 Cell Genesys, Inc. Multispecific chimeric receptors
US5723125A (en) * 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
ES2590912T3 (es) 1997-12-08 2016-11-24 Merck Patent Gmbh Proteínas de fusión heterodiméricas útiles para inmunoterapia dirigida y estimulación general del sistema inmunitario
ES2257303T3 (es) * 1999-07-12 2006-08-01 Genentech, Inc. Vectores de expresion y procedimientos.
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
MXPA02001417A (es) 1999-08-09 2002-08-12 Lexigen Pharm Corp Complejos multiples de citosina-anticuerpo.
CA2391080A1 (en) 1999-11-12 2001-05-25 Merck Patent Gesellschaft Mit Beschraenkter Haftung Erythropoietin forms with improved properties
HUP0204475A2 (en) 2000-02-11 2003-04-28 Merck Patent Gmbh Enhancing the circulating half-life of antibody-based fusion proteins
KR20030064275A (ko) 2000-06-29 2003-07-31 메르크 파텐트 게엠베하 면역싸이토카인 흡수 증강제와의 조합 치료에 의한항체-싸이토카인 융합 단백질 매개 면역 반응 증강
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
RU2003129528A (ru) * 2001-03-07 2005-04-10 Мерк Патент ГмбХ (DE) Способ экспрессии белков, содержащих в качестве компонента гибридный изотип антитела
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
EP1383785B1 (de) 2001-05-03 2011-03-16 Merck Patent GmbH Rekombinanter, tumorspezifischer antikörper und dessen verwendung
DK1454138T3 (da) 2001-12-04 2012-02-13 Merck Patent Gmbh Immunocytokiner med moduleret selektivitet
WO2004055056A1 (en) 2002-12-17 2004-07-01 Merck Patent Gmbh Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2
ES2305886T3 (es) 2003-12-30 2008-11-01 Merck Patent Gmbh Proteinas de fusion de il-7 con porciones de anticuerpo, su preparacion y su empleo.
RU2370276C2 (ru) 2003-12-31 2009-10-20 Мерк Патент Гмбх Fc-ЭРИТРОПОЭТИН СЛИТЫЙ БЕЛОК С УЛУЧШЕННОЙ ФАРМАКОКИНЕТИКОЙ
AU2005206277B2 (en) 2004-01-22 2011-06-23 Merck Patent Gmbh Anti-cancer antibodies with reduced complement fixation
RU2437893C2 (ru) 2004-12-09 2011-12-27 Мерк Патент Гмбх Варианты il-7 со сниженной иммуногенностью
RU2423381C2 (ru) 2005-07-25 2011-07-10 Трабьон Фармасьютикалз, Инк. Снижение количества в-клеток с использованием cd37-специфических и cd20-специфических связывающих молекул
ES2365046T3 (es) 2005-12-30 2011-09-21 Merck Patent Gmbh Anticuerpos anti-cd19 con inmunogenicidad reducida.
PL1966238T3 (pl) 2005-12-30 2012-09-28 Merck Patent Gmbh Warianty interleukiny-12p40 o polepszonej stabilności
NZ573646A (en) 2006-06-12 2012-04-27 Wyeth Llc Single-chain multivalent binding proteins with effector function
RU2531754C2 (ru) 2008-04-11 2014-10-27 ЭМЕРДЖЕНТ ПРОДАКТ ДИВЕЛОПМЕНТ СИЭТЛ,ЭлЭлСи,US Связывающееся с cd37 иммунотерапевтическое средство и его комбинация с бифункциональным химиотерапевтическим средством
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US10071748B2 (en) 2015-09-17 2018-09-11 Sony Corporation System and method for providing driving assistance to safely overtake a vehicle
WO2017053469A2 (en) 2015-09-21 2017-03-30 Aptevo Research And Development Llc Cd3 binding polypeptides
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
RU2769282C2 (ru) 2016-06-20 2022-03-30 Кимаб Лимитед Анти-PD-L1 и IL-2 цитокины
EP3534947A1 (de) 2016-11-03 2019-09-11 Kymab Limited Antikörper, kombinationen mit antikörpern, biomarker, verwendungen und verfahren
CN110592057B (zh) * 2019-09-27 2022-01-28 昆明理工大学 嵌合裂解酶ILTphg和编码此酶的多核苷酸

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4771002A (en) * 1984-02-24 1988-09-13 Lubrizol Genetics, Inc. Transcription in plants and bacteria

Also Published As

Publication number Publication date
AU633357B2 (en) 1993-01-28
DE69030579T2 (de) 1997-11-13
EP0493418B1 (de) 1997-04-23
DE69034022D1 (de) 2003-01-09
JP3051162B2 (ja) 2000-06-12
DE69030579D1 (de) 1997-05-28
ES2103274T3 (es) 1997-09-16
AU6335290A (en) 1991-04-18
DK0493418T3 (da) 1997-11-03
DK0765937T3 (da) 2003-03-24
EP0493418A4 (en) 1992-09-02
JPH05500310A (ja) 1993-01-28
EP0765937A1 (de) 1997-04-02
ATE152174T1 (de) 1997-05-15
CA2066612A1 (en) 1991-03-21
EP0765937B1 (de) 2002-11-27
EP0493418A1 (de) 1992-07-08
CA2066612C (en) 1998-12-08
WO1991004329A1 (en) 1991-04-04
ES2187598T3 (es) 2003-06-16
DE69034022T2 (de) 2003-07-10

Similar Documents

Publication Publication Date Title
ATE152174T1 (de) Verfahren zur herstellung von fusionsproteinen
AU2894289A (en) Domain-modified constant region antibodies
MY157028A (en) Mammalian cytokine, related reagents
KR890002404A (ko) 안정하고 생존가능한 재조합 동물 세포 바이러스 벡터의 제조방법
DE68929453D1 (de) Osteogene Vorrichtungen
NL300197I1 (de)
PT83065A (de) Fusionsproteine verfahren zu ihrer herstellung und ihre verwendung
DK1114864T4 (da) Pattedyrcelleoverfladeantigener samt tilhørende reagenser
YU150891A (sh) Rekombinantna genetska informacija
DK0646646T3 (da) System til ekspression af Lck-protein
DE3683447D1 (de) Verfahren zur herstellung von humanlysozym.
AU6989687A (en) Preparation of factor XIIIa by gene manipulation
ATE265533T1 (de) Saeugetierchemokine
PT97427A (pt) Processo para a preparacao de proteinas de fusao de tendamistato em estreptomicetas
MX9603266A (es) Genes de timocina de mamiferos.
DE59712771D1 (de) Nebenhoden-spezifisches Rezeptorprotein und dessen Verwendung
PT81253B (pt) Processo para a preparacao de uma sequencia de sinal sintetica para o transporte de proteinas em sistemas de expressao
NO173194C (no) Fremgangsmaate for fremstilling av proinsulin
IE881338L (en) A process for the preparation of foreign proteins in¹streptomycetes
AR002004A1 (es) Proteina slam, anticuerpo o un fragmento del mismo que se fija a dicha proteina, metodo de purificacion, acido nucleico que codifica dicha proteina,vector de expresion, equipo que la contiene, metodo de deteccion, metodo de modulacion y metodo para preparar una composicion farmaceutica.
WO2000034335A3 (en) 'death domain' containing receptors
DE68917520D1 (de) Verfahren und Systeme zur Herstellung von HIV-Antigenen.
DK0487229T3 (da) DNA, der koder for et protein, som binder til enhanceren for alfa-føtoproteingenet
KR890013177A (ko) 신규폴리펩티드 및 그것을 코우드하는 dna

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0765937

Country of ref document: EP

REN Ceased due to non-payment of the annual fee